Chengyi Pharmaceuticals: The net profit attributable to shareholders in 2025 is expected to decrease by 2.78% year-on-year, with a proposed dividend of 3 yuan per share.

On April 23, Chengyi Pharmaceutical announced that it is expected to achieve total operating income of 812 million yuan in 2025, a year-on-year increase of 13.72%; the net profit attributable to shareholders of the listed company is expected to be 195 million yuan, a year-on-year decrease of 2.78%; and the basic earnings per share is 0.61 yuan. On April 22, 2026, the company held the fifth meeting of the fifth board of directors to review and approve the profit distribution plan for 2025: it is proposed to distribute profits based on the total share capital registered on the equity distribution record date, with a cash dividend of 3 yuan for every 10 shares to be distributed to all shareholders, and a bonus issue of 4 shares for every 10 shares from the capital reserve. The remaining undistributed profits will be carried over to the next fiscal year. This proposal must be submitted to the shareholders meeting for approval before implementation.